NASDAQ:ACLX

Arcellx Stock Insider Trading

Healthcare > Biotechnology

Buy ACLX

*Your capital is at risk

$115.07

+0 (+0%)

At Close: Jun 03, 2026

Arcellx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -63.73. In total, the insiders bought 1.66M and sold 6.21M ACLX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-63.73
● Buy	1.66M shares
● Sell	6.21M shares
32% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 28, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -63.73. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Buy	Stock Option (right to buy) M-Exempt	Lubner David Charles Director	Director	6 000 Value: $37.7K
Jan 14, 2026 Sell	Common Stock S-Sale	Heery Christopher Chief Medical Officer	Officer	5 882 Value: $403.0K
Jan 13, 2026 Sell	Common Stock S-Sale	Heery Christopher Chief Medical Officer	Officer	7 437 Value: $487.2K
Jan 12, 2026 Sell	Common Stock S-Sale	Heery Christopher Chief Medical Officer	Officer	6 131 Value: $393.3K
Jan 06, 2026 Buy	Restricted Stock Unit M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	20 530 Value: $1.27M
Jan 06, 2026 Buy	Common Stock M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	20 530 Value: $1.27M
Jan 06, 2026 Buy	Restricted Stock Unit M-Exempt	Elghandour Rami See Remarks	Officer	55 991 Value: $3.47M
Jan 06, 2026 Buy	Common Stock M-Exempt	Heery Christopher Chief Medical Officer	Officer	13 064 Value: $810.8K
Jan 06, 2026 Buy	Restricted Stock Unit M-Exempt	Heery Christopher Chief Medical Officer	Officer	13 064 Value: $810.8K
Jan 06, 2026 Buy	Common Stock M-Exempt	Elghandour Rami See Remarks	Officer	55 991 Value: $3.47M
Jan 03, 2026 Buy	Common Stock M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	15 340 Value: $1.77M
Jan 03, 2026 Buy	Restricted Stock Unit M-Exempt	Heery Christopher Chief Medical Officer	Officer	16 520 Value: $1.90M
Jan 03, 2026 Buy	Common Stock M-Exempt	Heery Christopher Chief Medical Officer	Officer	16 520 Value: $1.90M
Jan 03, 2026 Buy	Common Stock M-Exempt	Elghandour Rami See Remarks	Officer	53 098 Value: $6.11M
Jan 03, 2026 Buy	Restricted Stock Unit M-Exempt	Elghandour Rami See Remarks	Officer	53 098 Value: $6.11M
Jan 03, 2026 Buy	Restricted Stock Unit M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	15 340 Value: $1.77M
Jan 02, 2026 Buy	Restricted Stock Unit A-Award	Elghandour Rami See Remarks	Officer	208 333 Value: $13.2M
Jan 02, 2026 Buy	Restricted Stock Unit M-Exempt	Heery Christopher Chief Medical Officer	Officer	13 021 Value: $824.8K
Jan 02, 2026 Buy	Common Stock M-Exempt	Heery Christopher Chief Medical Officer	Officer	13 021 Value: $824.8K
Jan 02, 2026 Buy	Restricted Stock Unit A-Award	Heery Christopher Chief Medical Officer	Officer	67 708 Value: $4.29M
Jan 02, 2026 Buy	Common Stock M-Exempt	Elghandour Rami See Remarks	Officer	55 459 Value: $3.51M
Jan 02, 2026 Buy	Restricted Stock Unit M-Exempt	Elghandour Rami See Remarks	Officer	55 459 Value: $3.51M
Jan 02, 2026 Buy	Common Stock M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	20 496 Value: $1.30M
Jan 02, 2026 Buy	Restricted Stock Unit M-Exempt	Gilson Michelle Chief Financial Officer	C-Suite Officer	20 496 Value: $1.30M
Jan 02, 2026 Buy	Restricted Stock Unit A-Award	Gilson Michelle Chief Financial Officer	C-Suite Officer	88 542 Value: $5.61M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCELLX, INC.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent Sp...

Read Full Profile Here